Cardiovascular disease (CVD) contributes substantially to the overall morbidity of HIV-infected individuals. Factors that epidemiologically and prospectively are the strongest predictors of .atherosclerosis are dyslipidemia and impairmen of intracellular cholesterol metabolism. Dyslipidemia in HIV-infected patients has been attributed mainly to antiretroviral drugs, in particular protease inhibitors, but specific mechanisms responsible for dyslipidemia have not been fully characterized. Even less is known about changes in lipid metabolism induced by HIV infection itself. In this application we propose a prospective study with HIV-infected patients to characterize changes in metabolism and functionality of High Density Lipoprotein (HDL), the key anti-atherogenic lipoprotein in the blood, associated with HIV-1 infection and anti-retroviral drugs. We will also correlate these changes with the surrogate measures of progression of atherosclerosis in these patients. Studies in vitro will address the mechanism of HIV-mediated effect on HDL The following Specific Aims are proposed: .
Specific Aim 1 : To characterize effects oLHIV disease on atherosclerosis and metabolic dysregulation. .
Specific Aim 2 : To characterize the effect of HIV disease on HDL composition and structure.
Specific Aim 3 : To characterize effects of HIV disease on HDL functionality.
Specific Aim 4 : To characterize cellular mechanisms responsible for impairment of HDL metabolism. . Research described in this proposal is a mUlti-PI program that will rely on collaborative efforts of clinical cardiologists, basic science cardiovascular researchers and virologists at three sites: the George Washington University, Harvard University and BakerlDI Heart and Diabetes Research Institute.
The proposed research is highly relevant to Public Health as it investigates the reason for high risk of atherosclerosis in HIV-infected subjects. Given that 10-30% of HIV-infected individuals present evidence of some form of cardiovascular disease, and atherosclerosis is the main underlying cause of cardiovascular disease, atherosclerosis becomes one of the main complications of HIV disease. However, mechanisms connecting HIV infection and anti-HIV treatment with development of atherosclerosis are not fully understood, making proposed study highly significant both for basic science and clinical research.
|Brichacek, Beda; Darwish, Christina; Popratiloff, Anastas et al. (2014) HIV-1 infection of macrophages induces retention of cholesterol transporter ABCA1 in the endoplasmic reticulum. AIDS Res Hum Retroviruses 30:947-8|
|Prasad, Vinayaka R; Bukrinsky, Michael I (2014) New clues to understanding HIV nonprogressors: low cholesterol blocks HIV trans infection. MBio 5:e01396-14|
|Haller, Jorge F; Cavallaro, Paul; Hernandez, Nicholas J et al. (2014) Endogenous *-glucocerebrosidase activity in Abca12ýýý/ýýýepidermis elevates ceramide levels after topical lipid application but does not restore barrier function. J Lipid Res 55:493-503|
|Jennelle, Lucas; Hunegnaw, Ruth; Dubrovsky, Larisa et al. (2014) HIV-1 protein Nef inhibits activity of ATP-binding cassette transporter A1 by targeting endoplasmic reticulum chaperone calnexin. J Biol Chem 289:28870-84|
|Rose, Honor; Low, Hann; Dewar, Elizabeth et al. (2013) The effect of HIV infection on atherosclerosis and lipoprotein metabolism: a one year prospective study. Atherosclerosis 229:206-11|
|Cui, Huanhuan L; Grant, Angela; Mukhamedova, Nigora et al. (2012) HIV-1 Nef mobilizes lipid rafts in macrophages through a pathway that competes with ABCA1-dependent cholesterol efflux. J Lipid Res 53:696-708|
|Morrow, Matthew P; Grant, Angela; Mujawar, Zahedi et al. (2010) Stimulation of the liver X receptor pathway inhibits HIV-1 replication via induction of ATP-binding cassette transporter A1. Mol Pharmacol 78:215-25|